



RGMG & CO.

CHARTERED ACCOUNTANTS
120, Rajendra Bhawan, Rajendra Place,
New Delhi-110 008 Phone : (91)-(11) 2576 1681
Email : rajesh@rgmg.org, manoj@rgmg.org

INDEPENDENT AUDITORS' REPORT

To, The Members
Sceptre Medical (India) Private Limited

Report on the Standalone Financial Statements


Opinion

We have audited the accompanying standalone financial statements of **Sceptre Medical (India) Private Limited** ("the Company"), which comprise the Balance Sheet as at 31st March, 2025, and the Statement of Profit and Loss for the year then ended, and notes to the financial statements, including a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2025, and profit for the year ended on that date.

Basis for Opinion

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the Standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion on the standalone financial statements.



Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Information other than the financial statements and auditors' report thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Annual report, but does not include the standalone financial statements and our auditor's report thereon. The annual report is expected to be made available to us after the date of this auditor's report.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position and financial performance of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company



and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a



material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedure that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls systems in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to



communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. Being a small Company, the provisions of the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of section 143(11) of the Act is not applicable to the Company.
2. As required by Section 143 (3) of the Act, we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Balance Sheet and the Statement of Profit and Loss dealt with by this Report are in agreement with the books of account.
 - d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 as amended.
 - e) On the basis of the written representations received from the directors as on 31st March, 2025 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2025 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f) Since the Company's turnover as per last audited financial statements is less



than Rs. 50 Crores and its borrowings from banks and financial institutions at any time during the year is less than Rs 25 Crore, the Company is exempted from getting an audit opinion with respect to the adequacy of the financial controls over financial reporting of the Company and the operating effectiveness of such controls vide notification dated June 13, 2017; and

g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:


- i. The Company does not have any pending litigations which would impact its financial position.
- ii. The company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
- iv. a) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
b) The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding,



whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

- c) Based on such audit procedures that we have considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material mis-statement.
- v. The company has not declared or paid dividend during the year.
- vi.. Based on our examination which included test checks the Company has used accounting software maintaining its books of account, which have a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the respective software. Further, for the periods where audit trail (Edit Log) facility was enabled and operated throughout the year for the respective accounting software, we did not come across any instance of the audit trail feature being tampered with.

For RGMG & CO.
Chartered Accountants
FRN No. 006329N



Rajesh Gupta

Partner

Membership No. 096737

Place: New Delhi

Date: 01.08.2025

UDIN: 25096737BMMJJU7542



Sceptre Medical (India) Private Limited
Balance Sheet as at 31st March, 2025

In Rs.,000

Particulars	Note No	2025	2024
	2		
I. EQUITY AND LIABILITIES			
Shareholders' Funds			
Share Capital	2	11719.44	11719.44
Reserve and Surplus	3	118788.96	79740.08
Non-current liabilities			
Long-Term Borrowings	4	48740.98	63389.77
Long-Term Provisions	5	4987.70	6689.51
Current liabilities			
Short-Term Borrowings	6	37930.88	19525.93
Trade Payables	7	23251.20	9284.25
Other Current Liabilities	8	17180.11	12241.85
Short Term Provisions	9	10959.81	6020.24
TOTAL		273559.08	208611.06
II. ASSETS			
Non Current Assets			
Property, Plant & Equipment	10	128896.18	79552.66
Non Current Investments	11	8194.00	29717.03
Other Non Current Assets	12	3380.65	1568.42
Current Assets			
Inventories	13	71197.39	41365.60
Trade Receivable	14	52392.06	47143.62
Cash and Cash Equivalents	15	5867.94	4776.26
Short Term Loan and Advances	16	2251.48	3855.17
Other Current Assets	17	1379.38	632.29
TOTAL		273559.08	208611.06

Significant Accounting Policies Notes on
Financial Statements

As per our report of even date

For RGMG & CO.

Chartered Accountants

Firm Reg No.: 06329N

Rajesh Gupta

Partner

M.No. 096737

New Delhi



Sanjay Manocha

Director

DIN:00076997

Yogesh Sachdeva

Director

DIN:00077095

Kartik Palta

Director

DIN:01543913

Archana Manocha

Director

DIN:02020796

Sceptre Medical (India) Private Limited
Statement of Profit & Loss for the year ended 31st March, 2025

In Rs.,000

	Particulars	Note No	2025	2024
	Income:			
I	Revenue from operations	18	286945.06	222371.82
	Other Income	19	-807.64	1659.17
	Total Income		286137.41	224030.99
II	Expenses:			
	Cost of Material Consumed	20	134797.31	67498.87
	Purchase Stock in Trade	21	40842.20	60506.64
	Change in Inventories	22	-9891.17	1369.54
	Employee benefits expenses	23	36543.34	32085.26
	Finance Cost	24	6481.84	6531.00
	Depreciation and amortization expenses	25	7007.06	6758.14
	Other Expenses	26	22275.19	24879.68
	Total expenses		238055.76	199629.13
III	Profit before tax		48081.65	24401.86
IV	Tax expenses:			
	Current Tax		12500.00	6500.00
	Deferred Tax		-3528.11	879.82
V	Profit (Loss) for the period (III-IV)		39109.76	17022.04
VI	Earning per equity share:			
	Basic & Diluted		33	15

Significant Accounting Policies Notes on
Financial Statements

As per our report of even date

For RGMG & CO.

Chartered Accountants

Firm Reg No.: 06329N




Rajesh Gupta

Partner

M.No. 096737

New Delhi





Sanjay Manocha

Director


DIN:00076997



Yogesh Sachdeva

Director


DIN:00077095



Kartik Palta

Director

DIN:01543913



Archana Manocha

Director

DIN:02020796

Sceptre Medical (India) Private Limited

Notes forming part of the Financial Statements for the year ended March 31,2025

1 SIGNIFICANT ACCOUNTING POLICIES

1.1 Corporate Information

Sceptre Medical (India) Private Limited("the Company) was incorporated on 24th June, 2010 under the Companies Act,1956 as a Private Limited Company. The Company is engage in the business of medical devices, medical equipment, surgical items, surgical equipment, pathological/laboratory items and other related goods.

1.2 Basis of Preparation of Financial Statements

The financial statements have been prepared in accordance with the generally accepted accounting principals in india under the historical cost convention on accrual basis. Pursuant to section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules 2014, till the standards of accounting or any addendum thereto are prescribed by central Government in consultantion and recommendation of the National Financial Reporting Authority, the existing Accounting Standards notified under the Companies Act, 1956 shall to apply. Consequently, these financial statements have been prepared to comply in all material aspects with the accounting standards notified under section 211(3C) of Companies ACT, 1956 (Companies (Accounting Standards) Rules 2006, as amended) and other relevant provisions of the Companies Act, 2013

1.3 Use of Estimates

The preparation of finanical statement requires estimates and assumptions to be made that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Difference between the actual results and estimates are recongnised in the period in which the results are known/materialised.

1.4 Cash and Cash equivalentents

Cash comprises cash on hand and demand deposits with banks, Cash equivalentents are short term,highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

1.5 Cash Flow Statement

Cash flows are reported using the indirect menthod, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non cash nature and any defeerals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financial activities of the company are segregated based on the available information.



1.6 Property, Plant and Equipment

Property, Plant and Equipment are stated at cost, less accumulated depreciation/ amortisation. Costs includes all expenses incurred to bring the assets to its present location and condition.

1.7 Depreciation and Amortisation

Depreciation on Property, Plant & Equipment is provided to the extent of depreciation amount on Stright Line Method (SLM) over the estimated useful life of the Assets in the manner prescribed in Schedule II of the Act, as against the earlier practice of depreciating at the rates prescribed in Schedule XIV of companies Act 1956,

Effective from 1st April 2014, the Company depreciates its fixed assets over the useful life

Depreciation on additions to assets or on sale / discardment of assets, is calculated prorata basis from the month of such addition or upto the month of such sale/discardment, as the case may be.

1.8 Impairment of Assets

An Asset is treated as impaired when the carrying cost of assets exceeds its recoverable value. An impairment loss is charged in Profit & Loss Account in the year in which an assets is identified as impaired. The impairment loss recognised in prior accounting period is reversed if there has been a change in the estimate of recoverable amount.

1.9 Foreign Currency Transactions

Purchases and Services revenue are accounted at daily rates. Exchange Fluctuations arising on payment or on realization are dealt with in the Statement of Profit & Loss. Monetary Assets and Monetary Liabilities are restated at the year end closing rate and any difference arising thereof has been dealt with in the statement of Profit & Loss to the extent its pertains to the current year.

1.10 Investments

Current Investments are carried at lower of cost and quoted/ fair value, computed category wise. Long Term Investment are stated at cost. Provisions for diminution in the value of long-term investment is made only if such a decline is other than temporary.

1.11 Inventories

Items of inventories are measured at lower of cost and net realisable value after providing for obsolescence, if any.



1.12 Revenue Recognition

Revenue is recognized only when it can be reliably measured and it is reasonable to expect ultimate collection. Revenue from operations includes sale of goods, services, sales tax, service tax, excise duty and sales during trial run period, adjustment for discounts (net), Value Added Tax (VAT) and gain/loss on corresponding hedge contracts. Dividend Income is recognised when right to receive is established. Interest income is recognised on time proportion basis taking into account the amount outstanding and rate applicable.

1.13 Borrowing Costs

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalised as part of the cost of such assets. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use. All

1.14 Earning Per Share

Basic Earning per Share is computed by dividing Profit after tax (including the post tax effect of extraordinary items, if any) by the number of equity share outstanding during the year.

1.15 Provisions for Current and Deferred Tax

Provisions for current tax is made after taking into consideration benefits admissible under the provisions of the Income Tax Act, 1961. Deferred tax resulting from "timing difference" between taxable and accounting income is accounted using the tax rates and laws that are enacted or substantively enacted as on the balance sheet date. Deferred tax assets is recognised and carried forward only to the extent that there is a virtual certainty that the asset will be realised in future

1.16 Provisions, Contingent Liabilities and Contingent Assets

Provisions involving substantial degree of estimation in measurement are recognized when there is present obligation as a result of past events and it is probable that there will be an outflow of resources. Contingent Liabilities are not recognised but are disclosed in the notes. Contingent Assets are neither recognized nor disclosed in the financial statements.

1.17 Note on Provision for Gratuity and Leave Encashment

The Company had not made any provision towards gratuity and leave encashment liability in the earlier years since its incorporation. During the financial year 2024-25, the Company has obtained an actuarial valuation of gratuity and leave encashment liability from a registered valuer in accordance with the requirements of Accounting Standard (AS) 15 "Employee Benefits".

Based on the actuarial valuation as at March 31, 2025, the following provisions have been recognized in the financial statements for the first time:

Gratuity Liability: Rs. 17,02,260

Leave Encashment Liability: Rs. 1,69,076



Accordingly, the total provision of Rs.18,71,336 has been created and charged to the Statement of Profit and Loss for the year ended March 31, 2025.

Management believes that the recognition of such liabilities in the current year appropriately represents the Company's obligation towards its employees as at the balance sheet date.

1.18 The MCA Vide Notification dated 24th March 2021 has amended Schedule III to the Companies Act, 2013 in respect of certain disclosures are applicable from 1st April, 2021. The Company incorporated the changes as per the said amendment in the

- (I) The Companies has no transactions with Companies Struck off under section 248 of the Companies Act, 2013 or Section 560 of the Companies Act, 1956 during the year
- (ii) The Company has not traded or invested in Crypto Currency or Virtual Currency during the year.
- (iii) The Company do not have any Benami property, where any proceeding has been initiated or pending against the company for holding any Benami Property.
- (iv) The Company do not have any charge or satisfaction which is yet to be registered with ROC beyond the statutory period.
- (v) The Company have not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the intermediary shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
 - (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- (vi) The Company have not received any funds from any person(s) or entity(ies). Including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
 - (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- (vii) The Company does not have any loans and advances in the nature of loans to promoters, directors, KMP and other related parties.

1.19 Additional Information:

		In Rs.,000	
Particulars	31.03.25	31.03.24	
1 Value of Imports			
2 Expenditure in Foreign Currency			
-Outward Remittance	--		
- Travel Expenditure	421.575		
3 Consumption of imported Raw Material	--	--	
components and spare parts			
4 Earning in foreign Currency			
5 Amount remitted in foreign currency	--		
towards Dividend			



1.18 Disclosure as per Accounting Standard - 18 on 'Related Party Disclosures'

Following are the related parties and transactions made with them during the year.

- | | |
|---|---|
| - Key Management Personnel (KMP) | : Mr. Sanjay Manocha |
| Director of the Company | : Mr. Kartik Palta |
| Director's Son | Mr. Yogesh Sachdeva |
| Director's Son | Ms. Archana Manocha |
| | Mr. Siddhartha Manocha |
| | |
| - Entities in which KMP/Relatives of KM | : M S Medicals Private Limited |
| can exercise significant influence | : Sceptre Medical Devices Private Limited |

Detail of related party transactions during the year ended 31 March, 2025

			(In Rs.000)
		2025	2024
Salary			
Mr Sanjay Manocha		3900.00	3600.00
Mr. Kartik Palta		930.00	-
Mr. Yogesh Sachdeva		750.00	-
Ms. Archana Manocha		2700.00	2400.00
Mr. Siddhartha Manocha		975.00	1100.00
Purchase of Good			
M S Medicals Medical Private Limited		-	703.00
Sceptre Medical Devices Private Limited		53.39	32.03
Sale of Goods			
M S Medicals Medical Private Limited		86122.63	71672.27
Sceptre Medical Devices Private Limited		49.65	84.25
Balance outstanding at the end of the year			
M S Medicals Medical Private Limited	CR	206.07	8301.30
Sceptre Medical Devices Private Limited		-	18.85

1.19 Detail of Current Maturities of Long Term Borrowings as below:

		Long Term	Short Term	Total
1	SIDBI-	48740.98	22734.00	71474.98
		48740.98	22734.00	71474.98



1.4 Key Financial Ratios are as below:

Sr.No	Ratio	Current Year			Previous Year			In Rs.,000 % Variance
		Numerator	Denominator	Ratio	Numerator	Denominator	Ratio	
1	Current Ratio							
	Current Assets							
	Current Liabilities							
	Current Assets							
	Inventories	71197.39			41365.60			
	Trade receivable	52392.06			47143.62			
	Cash and cash equivalents	5867.94			4776.26			
	Short-term loans and advances	2251.48			3855.17			
	Other Current Assets	1379.38			632.29			
	Total	133088.25			97772.95			
	Current Liabilities							
	Trade payables		23251.20			19525.93		
	Short Term Loans		37930.88			9284.25		
	Other current liabilities		17180.11			12241.85		
	Provision for Taxation		10959.81			6020.24		
	Total		89322.00	1.49		47072.27	2.08	-28.27
2	Debt-Equity Ratio							
	Total Debts							
	Shareholders Equity							
	Debts							
	Long-term borrowings	48740.98			63389.77			
	Short-term borrowings	37930.88			19525.93			
		86671.86			82915.70			
	Shareholders Equity							
	Share Capital		11719.44			11719.44		
	Reserve and surplus		118788.96			79740.08		
			130508.40	0.66		91459.52	0.91	-26.75
3	Debt Service Coverage Ratio							
	Earning available for debts service							
	Debts Service							
	Earning for Debts Services							
	Net Profit before Taxes	48081.65			24401.86			
	Add: Depreciation	7007.06			6758.14			
	Interest	6481.84			6531.00			
	Total	61570.55			37691.00			
	Debts Service							
	Interest Payment		6481.84			6531.00		
	Principal =Short Term & Long -term		37930.88			19525.93		
			44412.72	1.39		26056.93	1.45	-4.16
4	Return on Equity Ratio							
	Net Profit after Taxes							
	Shareholder Equity							
	Net Profit After Tax	35581.65			17901.86			
		35581.65			17901.86			
	Shareholders Equity							
	Share Capital		11719.44			11719.44		
	Reserve and surplus		118788.96			79740.08		
			130508.40	0.2726		91459.52	0.196	39.29



5	Inventory Turnover Ratio						
	Cost of Goods Sold/Sales						
	Average Inventory						
	Cost of Goods Sold						
	Cost of Material Consumed	134797.31			67498.87		
	Purchase of Stock-in-Trade	40842.20			60506.64		
	Change in Inventory of Stock	-9891.17			1369.54		
	Custom Duty	62.44			28.86		
	Power & Fuel	2554.90			1806.33		
	Fee & Taxes	264.58			402.94		
	Total	168630.25			131613.17		
	Average Stock						
	Opening Stock		41365.60			40953.64	
	Closing Stock		71197.39			41365.60	
	Total		112562.99			82319.24	
	Average Turnover		56281.49	2.99619		41159.62	3.20 -6.30
6	Trade Receivable Turnover Ratio						
	Net Credit Sales						
	Average Accounts Receivable						
	Net Credit Sales						
	Sales less Sales Return	286945.06			222371.82		
		286945.06			222371.82		
	Average Account Receivable						
	Opening Balance		47143.62			22625.52	
	Closing Balance		52392.06			47143.62	
	Average Account Receivable		49767.84	5.76567		34884.57	6.375 -9.55
7	Trade Payable Turnover Ratio						
	Net Credit Purchases						
	Average Accounts Payable						
	Net Credit Purchases						
	Purchases less Purchases Return	195580.13			129787.00		
	Total	195580.13			129787.00		
	Average Account Payable						
	Opening Balance		9284.25			21227.63	
	Closing Balance		23251.20			9284.25	
	Average Account Payable		32535.45	12.0226		30511.88	8.507 41.32
8	Net Capital Turnover Ratio						
	Net Sales						
	Net Working Capital						
	Net Sales	286945.06			222371.82		
	Net Working Capital						
	Current Assets		133088.25			98521.82	
	Less: Current Liabilities		89322.00			47072.27	
			43766.25	6.55631		51449.55	4.322 51.69
9	Net Profit Ratio						
	Net Profit						
	Sales						
	Net Profit (After Taxes)	35581.65			17901.86		
			286945.06	0.124		222371.82	0.081 54.03



10	Return on Capital Employed					
	Earning before Interest and Taxes					
	Capital Employed					
	Earning before Interest and Taxes					
	Net Profit	48081.65		24401.86		
	Add: Interest	6481.84		6531.00		
	Total	54563.49		30932.87		
	Capital Employed					
	(Total Assets -Current Liabilities)					
	Total Assets	273559.08		208611.06		
	Less: Current Liabilities	-89322.00		-47072.27		
		362881.08	0.15036	255683.33	0.121	24.29
11	Return on Investment					
	Profit	-		-		
	Investment	8194.00	-	29717.03	-	

Reason for Variance

- 1 Current Liabilities increased, therefore ratio decreased.
- 2 Shareholders Equity increased, therefore ratio decreased.
- 3 There is no significant change in the key financial ratio (Less than 25%)
- 4 Net Profit increased, therefore ratio increased
- 5 There is no significant change in the key financial ratio (Less than 25%)
- 6 There is no significant change in the key financial ratio (Less than 25%)
- 7 Purchase is increased, therefore ratio increased,
- 8 Net Sales is increased, therefore ratio increased,
- 9 Net Profit increased, therefore ratio increased
- 10 There is no significant change in the key financial ratio (Less than 25%)
- 11 There is no earning from Investment



Notes on Financial Statement for the year ended 31st March, 2025

In Rs.,000

2025 2024

The previous year figures have been regrouped / reclassified, wherever necessary to confirm to the current year presentation

2. SHARE CAPITAL

Authorized Share Capital :

2000000 Equity shares of Rs.10/- each
(Previous Year 50000 Equity Shares)

20000.00 10000.00

Issued,Subscribed and Paid up :

1171944 Equity Shares of Rs.10/- each fully paid up
(Previous Year 1171944 Equity Shares of Rs.10/- each)

11719.44 11719.44

Total 11719.44 11719.44

The details of Shareholders holding more than 5% Shares:

Name of the Sharholders	2025		2024	
	No. of Share	% held	No. of Share	% held
Sanjay Manocha	292986	25.00	609055	51.97
Archna Manocha	135167	11.53	522264	44.56
Siddharth Manocha	40625	3.47	40625	3.47
Kartik Palta	169931	14.50	-	-
Yogesh Sachdeva	234389	20.00	-	-
Sukesh Arora	140633	12.00	-	-
Mona Sachdeva	93756	8.00	-	-
Charu Palta	64457	5.50	-	-

The details of Shareholding of Promoters:

Name of the Sharholders	2025		2024	
	No. of Share	% held	No. of Share	% held
Sanjay Manocha	292986	25.00	609055	51.97
Archna Manocha	135167	11.53	522264	44.56
Siddharth Manocha	40625	3.47	40625	3.47
Kartik Palta	169931	14.50	-	-
Yogesh Sachdeva	234389	20.00	-	-
Sukesh Arora	140633	12.00	-	-
Mona Sachdeva	93756	8.00	-	-
Charu Palta	64457	5.50	-	-

The Reconciliation of the numbers of shares outstanding is set out below:

	2025	2024
Equity Shares at the beginning of the year	1171944	1171944
Add: Share Issued during the year	-	-
Equity Shares at the end of the year	1171944	1171944

Terms/rights attached to Equity Shares

The company has only one class of equity shares having a par value of Rs.10 per share. All these shares have same rights and preferences with respect to payment of dividend, repayment of capital and voting.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.



3. RESERVES AND SURPLUS**Share Premium Account**

As per Last Balance Sheet

Add: During the year

Total(A)**2025****2024**

8250.48

8250.48

8250.48**8250.48****Profit & Loss Account**

As per Last Balance Sheet

Add: Profit for the year

Less: Previous Year Adjustment

Total(B)**Grand Total (A+B)**

71489.60

54627.69

39109.76

17022.04

60.87

160.14

110538.48**71489.60****118788.96****79740.08**

Notes on Financial Statement for the year ended 31st March, 2025

In Rs.,000

	2025	2024
--	------	------

4. LONG TERM BORROWINGS

Term Loan -Working Capital (SIDBI)	48740.98	53821.00
Business Term Loan	-	6681.37
Term Loan against Vehicle	-	2887.40
Total	48740.98	63389.77

Security

- (i) SIDBI Working Capital Loan secured by mortgage of Factory Building & Plant & Machinery
(ii) Term Loan against Vehicle is secured by hypothecation of Vehicle.

5. LONG TERM PROVISIONS

Deferred Tax Liability	3161.40	6689.51
Provision for Gratuity	1667.55	-
Provision for Leave Encashment	158.75	-
Total	4987.70	6689.51

6. SHORT TERM BORROWINGS

Term Loan -Working Capital (SIDBI)	22734.00	18235.00
Business Term Loan	-	300.00
Term Loan against Vehicle	-	990.93
Loan from Related Parties	15196.88	-
Total	37930.88	19525.93

Security

- (i) SIDBI Working Capital Loan secured by mortgage of Factory Building & Plant & Machinery
(ii) Term Loan against Vehicle is secured by hypothecation of Vehicle.

7. TRADE PAYABLES

(i) Micro, Small and Medium Enterprises		
-Less Than 1 Year	16803.45	8790.72
-1-2 Years	157.84	-
-2-3 Years	-	-
- More than 3 Years	-	-
(ii) Others		
-Less Than 1 Year	6289.91	493.53
(iii) Disputed Dues-MSME	-	-
(iii) Disputed Dues-Others	-	-
Total	23251.20	9284.25

8. OTHER CURRENT LIABILITIES

Statutory Dues Payable	5606.60	2998.52
Salary Payable	3430.03	1802.07
Expenses Payable	2936.02	1417.48
Other Current Liabilities	5207.45	4628.14
Advance From Customer	-	1276.98
Security Deposits	-	118.66
Total	17180.11	12241.85

9. SHORT TERM PROVISIONS

Income Tax Provisions	10914.77	6020.24
Provision for Gratuity	34.72	-
Provision for Leave Encashment	10.32	-
Total	10959.81	6020.24



In Rs.,000

10. FIXED ASSETS

Particulars	Original Cost			As at		Depreciation		Total	Net Book Value	
	As at 01.04.24	Addition	Deletion	31.03.25	As at 01.04.24	For the Year	Adjusted		As at 31.03.25	As at 31.03.24
TANGIBLE ASSETS:										
Factory Building	38951.07	53550.00	-	92501.08	4627.09	776.72	-	5403.81	87097.27	34323.98
Plant & Machinery	40818.41	2116.50	-	42934.91	12012.28	2581.68	-	14593.97	28340.94	28806.13
Computer	1703.25	225.05	113.56	1814.74	1367.69	199.61	107.88	1459.42	355.32	335.56
Furniture & Fixture	5998.88	370.95	-	6369.83	1561.34	575.38	-	2136.72	4233.11	4437.54
Delivery Van	1153.34	-	-	1153.34	308.29	137.02	-	445.30	708.04	845.05
Vehicle	13625.10	-	-	13625.10	6614.87	1522.45	-	8137.32	5487.78	7010.23
Office Equipment	7275.90	93.35	-	7369.25	3518.38	1197.87	-	4716.24	2653.01	3757.53
Total (A)	109525.95	56355.85	113.56	165768.24	30009.94	6990.71	-	36892.78	128875.47	79516.00
INTANGIBLE ASSETS:										
Computer Software	192.11	-	-	192.11	155.05	16.35	-	171.40	20.71	37.06
Total (B)	192.11	-	-	192.11	155.05	16.35	-	171.40	20.71	37.06
Grand Total	109718.06	56355.85	113.56	165960.35	30165.00	7007.06	-	37064.17	128896.18	79553.06
Previous Year	103526.47	6191.60	-	109718.06	23407.26	6758.14	-	30165.40	79552.66	80119.21



Notes on Financial Statement for the year ended 31st March, 2025

In Rs.,000

	2025	2024
11. NON CURRENT INVESTMENTS		
Investment in Properties	8194.00	29717.03
Total	8194.00	29717.03
12. OTHER NON CURRENT ASSETS		
Security Deposit	3380.65	1568.42
Total	3380.65	1568.42
13. INVENTORIES		
Stock-in-Trade	71197.39	41365.60
Total	71197.39	41365.60
14. TRADE RECEIVABLE		
(Unsecured and Considered Good)		
(i) Undisputed Trade Receivable-Considered Good		
- Less Than 6 Months	50983.74	45020.54
- 6 Months-1 Year	116.02	857.11
- 1 -2 Years	245.52	740.18
- 2 -3 Years	-	525.79
- More than 3 Years	1046.78	-
(ii) Undisputed Trade Receivable-Considered Doubtful	-	-
(iii) Disputed Trade Receivable-Considered Good	-	-
(v) Disputed Trade Receivable-Considered Doubtful	-	-
Total	52392.06	47143.62
15. CASH AND CASH EQUIVALENTS		
Balance with Banks	2031.67	1391.30
Cash in Hand	385.86	152.88
FDR with Banks	3450.42	3232.08
Total	5867.94	4776.26
16. Short Term Loans & Advances		
[Unsecured-Considered Good (Unless Otherwise Stated)]		
Advance Agt Purchase	382.58	3294.90
Other Advance	1771.12	142.88
Prepaid Expense	97.78	417.40
Total	2251.48	3855.17
17. OTHER CURRENT ASSETS		
[Unsecured-Considered Good (Unless Otherwise Stated)]		
VAT Refundable	105.10	105.10
GST Input Credit	256.39	212.62
I T Refund	134.42	181.03
GST Not Reflected	883.47	133.55
Total	1379.38	632.29



Notes on Financial Statement for the year ended 31st March, 2025

In Rs.,000

	2025	2024
--	------	------

18. REVENUE FROM OPERATIONS

Sale of Products	294160.63	241238.46
Less: Inter Unit Transfer	7215.58	18866.64
Total	286945.06	222371.82

19. OTHER INCOME

Interest on FDR	229.35	429.86
Reimbursement-Govt Schemes	375.00	1381.81
Loss on sale of Investment	-1411.99	-152.50
Total	-807.64	1659.17

20. COST OF MATERIAL CONSUMED

Opening Stock	35909.74	34128.25
Add: Purchase during the year	154737.92	69280.36
	190647.67	103408.61
Less: Closing Stock	55850.36	35909.74
Total	134797.31	67498.87

21. PURCHASE OF STOCK IN TRADE

Purchases of stock in trade	48057.78	79373.28
Less: Inter Unit Transfer	7215.58	18866.64
Total	40842.20	60506.64

22. CHANGES IN INVENTORIES OF FINISHED GOODS

Inventories at the end of the Year	15347.03	5455.86
Inventories at the beginning of the Year	5455.86	6825.39
Total	-9891.17	1369.54

23. EMPLOYEE COST BENEFIT

Wages, Salary & Incentives	32725.33	30765.89
Contribution to Provident and ESI Fund	1654.04	1197.86
Provision for Gratuity	1702.26	-
Provision for Leave Encashment	169.08	-
Staff Welfare	292.64	121.52
Total	36543.34	32085.26

24. FINANCE COST

Bank Charges	88.94	95.63
Bank Interest	6392.90	6435.38
Total	6481.84	6531.00

25. DEPRECIATION AND AMORTISATION EXPENSES

Depreciation and Amortisation	7007.06	6758.14
Total	7007.06	6758.14



26.OTHER OPERATING EXPENSES

Custom Duty	62.44	28.86
Clearing & Forwarding Charges	58.34	-
Power & Fuel	2554.90	1806.33
Repair & Maintance Expenses	1581.31	2375.13
Rent	2081.73	1869.29
Fright & Courier Charges	2681.58	2799.54
Conveyance & Travelling Expenses	3346.32	5727.47
Communication Expense	122.63	104.77
Office Expenses	498.48	585.01
Printing & Stationery Expenses	406.37	504.34
GST Expenses	516.30	178.07
Insurance Expenses	443.36	436.01
Fee & Taxes	264.58	402.94
Professional Fee	2569.25	2266.50
Testing fee	372.03	-
Packing Expenses	-	11.80
Audit Fee	125.00	125.00
Business Promotion	1359.81	2425.23
Discount Allowed	2115.37	1700.13
Commission	6.75	235.65
Water Charges	20.93	38.39
Security Charges	517.94	432.05
Festival Expenses	144.00	340.06
Tender Fee	-	245.46
Website Expenses	425.77	241.66
Total	22275.19	24879.68





RGMG & CO.

CHARTERED ACCOUNTANTS
120, Rajendra Bhawan, Rajendra Place,
New Delhi-110 008 Phone : (91)-(11) 2576 1681
Email : rajesh@rgmg.org, manoj@rgmg.org

INDEPENDENT AUDITORS' REPORT

**TO THE MEMBERS OF
Sceptre Medical (India) Private Limited**

Report on the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of **Sceptre Medical (India) Private Limited** ("*the holding & associate*") which comprises the Balance Sheet as at March 31, 2025, the Statement of Profit and Loss for the year then ended and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2025, and profit for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.



Information other than the financial statements and auditors' report thereon

The Company's management and board of directors is responsible for the preparation and presentation of the other information. The other information comprises the information included in the Annual Report including Annexures to Annual Report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Responsibility of Management for the Consolidated Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these consolidated financial statements that give a true and fair view of the financial position, financial performance in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.



The Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibility for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirement

1. Being a small company, the provisions of the companies (Auditor's Report) order 2020 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013 is not applicable to the company.
2. As required by Section 143(3) of the Act based on our audit, we report, to the extent applicable, that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - a) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - b) The Balance Sheet and the Statement of Profit and Loss dealt with by this Report are in agreement with the books of account.



- e) In our opinion, the aforesaid Consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act as applicable.

- d) On the basis of the written representations received from the directors as on 31st March, 2025 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2025 from being appointed as a director in terms of Section 164 (2) of the Act.
- e) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivatives contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which required to be transferred by the Company to the Investor Education and Protection Fund.
 - iv. In respect of management representations:
 - a) The Management has represented that, to the best of its knowledge and belief, , no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Company or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - b) The Management has represented that, to the best of its knowledge and belief, other than those as disclosed in the notes to the accounts , no funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Funding Parties or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.



- c) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e) contain any material mis-statement.
- v. The company has not declared or paid dividend during the year for the previous year.
- vi. Based on our examination which included test checks the Company has used accounting software maintaining its Books of accounts, which have a features of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the respective software. Further, for the periods where audit trail (edit log) facility was enabled and operated throughout the year for the respective accounting software, we did not come across any instance of the audit trail feature being tempered with and the audit trail has been preserved by the company as per the statutory requirements for record retention.

For RGMG & CO.
Chartered Accountants
Firm Registration No.06329N



Rajesh Gupta
Partner, M.No.096737
Place: New Delhi
Date: 02-09-2025
UDIN:25096737BMMJKH3091



Sceptre Medical (India) Private Limited
Consolidated Balance Sheet as at 31st March, 2025

In Rs.,000

Particulars	Note No	2025	2024
	2		
I. EQUITY AND LIABILITIES			
Shareholders' Funds			
Share Capital	2	11719.44	11719.44
Reserve and Surplus	3	119283.28	79740.08
Non-current liabilities			
Long-Term Borrowings	4	48740.98	63389.77
Long-Term Provisions	5	4987.70	6689.51
Current liabilities			
Short-Term Borrowings	6	37930.88	19525.93
Trade Payables	7	23251.20	9284.25
Other Current Liabilities	8	17180.11	12241.85
Short Term Provisions	9	10959.81	6020.24
TOTAL		274053.39	208611.06
II. ASSETS			
Non Current Assets			
Property, Plant & Equipment	10	128896.18	79552.66
Non Current Investments	11	8688.31	29717.03
Other Non Current Assets	12	3380.65	1568.42
Current Assets			
Inventories	13	71197.39	41365.60
Trade Receivable	14	52392.06	47143.62
Cash and Cash Equivalents	15	5867.94	4776.26
Short Term Loan and Advances	16	2251.48	3855.17
Other Current Assets	17	1379.38	632.29
TOTAL		274053.39	208611.06

Significant Accounting Policies Notes on
Financial Statements

As per our report of even date

For RGMG & CO.

Chartered Accountants

Firm Reg No.: 06329N



Rajesh Gupta

Partner

M.No. 096737

New Delhi



Sanjay Manocha

Director

DIN:00076997



Kartik Palta

Director


DIN:01543913



Yogesh Sachdeva

Director

DIN:00077095



Archana Manocha

Director

DIN:02020796



Sceptre Medical (India) Private Limited
Consolidated Statement of Profit & Loss for the year ended 31st March, 2025

In Rs.,000

	Particulars	Note No	2025	2024
	Income:			
I	Revenue from operations	18	286945.06	222371.82
	Other Income	19	-807.64	1659.17
	Total Income		286137.41	224030.99
II	Expenses:			
	Cost of Material Consumed	20	134797.31	67498.87
	Purchase Stock in Trade	21	40842.20	60506.64
	Change in Inventories	22	-9891.17	1369.54
	Employee benefits expenses	23	36543.34	32085.26
	Finance Cost	24	6481.84	6531.00
	Depreciation and amortization expenses	25	7007.06	6758.14
	Other Expenses	26	22275.19	24879.68
	Total expenses		238055.76	199629.13
III	Profit before tax		48081.65	24401.86
IV	Tax expenses:			
	Current Tax		12500.00	6500.00
	Deferred Tax		-3528.11	879.82
V	Profit (Loss) for the period (III-IV)		39109.76	17022.04
	Add: Share of Net Profit of Associates		494.31	-
			39604.07	17022.04
VI	Earning per equity share:			
	Basic & Diluted		34	15


Significant Accounting Policies Notes on
Financial Statements

As per our report of even date

For RGMG & CO.

Chartered Accountants

Firm Reg No.: 06329N



Rajesh Gupta

Partner

M.No. 096737

New Delhi





Sanjay Manocha

Director

DIN:00076997



Yogesh Sachdeva

Director

DIN:00077095



Kartik Palta

Director

DIN:01543913



Archana Manocha

Director

DIN:02020796

Sceptre Medical (India) Private Limited

Notes forming part of the Financial Statements for the year ended March 31, 2025

1 SIGNIFICANT ACCOUNTING POLICIES

1.1 Corporate Information

Sceptre Medical (India) Private Limited ("the Company") was incorporated on 24th June, 2010 under the Companies Act, 1956 as a Private Limited Company. The Company is engaged in the business of medical devices, medical equipment, surgical items, surgical equipment, pathological/laboratory items and other related goods.

1.2 Basis of Preparation of Financial Statements

The financial statements have been prepared in accordance with the generally accepted accounting principles in India under the historical cost convention on accrual basis. Pursuant to section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules 2014, till the standards of accounting or any addendum thereto are prescribed by central Government in consultation and recommendation of the National Financial Reporting Authority, the existing Accounting Standards notified under the Companies Act, 1956 shall apply. Consequently, these financial statements have been prepared to comply in all material aspects with the accounting standards notified under section 211(3C) of Companies Act, 1956 (Companies (Accounting Standards) Rules 2006, as amended) and other relevant provisions of the Companies Act, 2013.

1.3 Use of Estimates

The preparation of financial statement requires estimates and assumptions to be made that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Difference between the actual results and estimates are recognised in the period in which the results are known/materialised.

1.4 Cash and Cash equivalents

Cash comprises cash on hand and demand deposits with banks, Cash equivalents are short term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

1.5 Cash Flow Statement

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financial activities of the company are segregated based on the available information.



1.18 Disclosure as per Accounting Standard - 18 on 'Related Party Disclosures'

In Rs.,000

Following are the related parties and transactions made with them during the year.

- Key Management Personnel (KMP) : Mr. Sanjay Manocha
Director of the Company : Mr. Kartik Palta
Director's Son : Mr. Yogesh Sachdeva
Director's Son : Ms. Archana Manocha
Mr. Siddhartha Manocha
- Entities in which KMP/Relatives of KM: M S Medicals Private Limited
can exercise significant influence : Sceptre Medical Devices Private Limited

Detail of related party transactions during the year ended 31 March, 2025

	2025	(Rs.) 2024
Salary		
Mr Sanjay Manocha	3900.00	3600.00
Mr. Kartik Palta	930.00	-
Mr. Yogesh Sachdeva	750.00	-
Ms. Archana Manocha	2700.00	2400.00
Mr. Siddhartha Manocha	975.00	1100.00
Purchase of Good		
M S Medicals Medical Private Limited	-	703.00
Sceptre Medical Devices Private Limited	53.39	32.03
Sale of Goods		
M S Medicals Medical Private Limited	86122.63	71672.27
Sceptre Medical Devices Private Limited	49.65	84.25
Balance outstanding at the end of the year		
M S Medicals Medical Private Limited	206068 Cr	8301304 Dr
Sceptre Medical Devices Private Limited	-	18851 Dr

1.19 Detail of Current Maturities of Long Term Borrowings as below:

	Long Term	Short Term	Total
1 SIDBI-	48740.98	22734.00	71474.98
	48740.98	22734.00	71474.98



1.21 BASIS OF CONSOLIDATION

The Consolidated Financial Statement (CFS) has been prepared as per Equity Method in Accordance with Accounting Standard -21 (AS 21) on "Consolidated Financial Statements" and Accounting Standard -23 (AS 23) on "Accounting for Investments in Associates in Consolidated Financial Statements" as notified.

On acquisition of an associates, the Goodwill / Capital Reserve arising from such acquisition is included in the carrying amount of the Investment and also disclosed separately. Only share of Net Profit/Losses of associates is considered in Consolidated Statement of Profit and Loss. The carrying amount of the Investment in associates is adjusted by the share of Net Profit/Losses in the Consolidated Balance Sheet.

The Company considered in the Consolidated Financial Statements are:

Name	Sceptre Medical Devices Private Limited
Nature of Company	Associates
Country of Incorporation	India
Holding as on 31.03.2025	40%
Period of Consolidation	F Y 2024-2025

Additional Information required to be disclosed in terms of Schedule III of the Companies Act, 2013:

Name of Entity	Sceptre Medical Devices Private Limited

Non Current Assets		Share in Profit or Loss	
As % consolidated Net Assets	Amount (Rs. in Lakh)	As % consolidated Profit / Losses	Amount (Rs. in Lakh)
Current Year 3.17	66.88	--	4.94
Previous Year --	--	--	--



1.4 Key Financial Ratios are as below:

In Rs.,000

Sr.No	Ratio	Current Year		Previous Year		% Variance
		Numerator	Denominator Ratio	Numerator	Denominator Ratio	
1	Current Ratio					
	Current Assets					
	Current Liabilities					
	Current Assets					
	Inventories	71197.39		41365.60		
	Trade receivable	52392.06		47143.62		
	Cash and cash equivalents	5867.94		4776.26		
	Short-term loans and advances	2251.48		3855.17		
	Other Current Assets	1379.38		632.29		
	Total	133088.25		97772.95		
	Current Liabilities					
	Trade payables		23251.20		19525.93	
	Short Term Loans		37930.88		9284.25	
	Other current liabilities		17180.11		12241.85	
	Provision for Taxation		10959.81		6020.24	
	Total		89322.00		47072.27	2.08
			1.49			-28.27
2	Debt-Equity Ratio					
	Total Debts					
	Shareholders Equity					
	Debts					
	Long-term borrowings	48740.98		63389.77		
	Short-term borrowings	37930.88		19525.93		
		86671.86		82915.70		
	Shareholders Equity					
	Share Capital		11719.44		11719.44	
	Reserve and surplus		119283.28		79740.08	
			131002.72		91459.52	0.91
			0.66			-27.02
3	Debt Service Coverage Ratio					
	Earning available for debts service					
	Debts Service					
	Earning for Debts Services					
	Net Profit before Taxes	48081.65		24401.86		
	Add: Depreciation	7007.06		6758.14		
	Interest	6481.84		6531.00		
	Total	61570.55		37691.00		
	Debts Service					
	Interest Payment		6481.84		6531.00	
	Principal =Short Term & Long -term		37930.88		19525.93	
			44412.72	.00	26056.93	1.446
			1.39			-4.16
4	Return on Equity Ratio					
	Net Profit after Taxes					
	Shareholder Equity					
	Net Profit After Tax	35581.65		17901.86		
		35581.65		17901.86		
	Shareholders Equity					
	Share Capital		11719.44		11719.44	
	Reserve and surplus		119283.28		79740.08	
			131002.72		91459.52	0.196
			0.2716			38.76



5	Inventory Turnover Ratio						
	Cost of Goods Sold/Sales						
	Average Inventory						
	Cost of Goods Sold						
	Cost of Material Consumed	134797.31			67498.87		
	Purchase of Stock-in-Trade	40842.20			60506.64		
	Change in Inventory of Stock	-9891.17			1369.54		
	Custom Duty	62.44			28.86		
	Power & Fuel	2554.90			1806.33		
	Fee & Taxes	264.58			402.94		
	Total	168630.25			131613.17		
	Average Stock						
	Opening Stock		41365.60			26268.16	
	Closing Stock		71197.39			41365.60	
	Total		112562.99			67633.76	
	Average Turnover		56281.49	2.99619		33816.88	3.89
							-23.02
6	Trade Receivable Turnover Ratio						
	Net Credit Sales						
	Average Accounts Receivable						
	Net Credit Sales						
	Sales less Sales Return	286945.06			222371.82		
		286945.06			222371.82		
	Average Account Receivable						
	Opening Balance		47143.62			18524.59	
	Closing Balance		52392.06			47143.62	
	Average Account Receivable		49767.84	5.76567		32834.10	6.773
							-14.87
7	Trade Payable Turnover Ratio						
	Net Credit Purchases						
	Average Accounts Payable						
	Net Credit Purchases						
	Purchases less Purchases Return	195580.13			129787.00		
	Total	195580.13			129787.00		
	Average Account Payable						
	Opening Balance		9284.25			9497.97	
	Closing Balance		23251.20			9284.25	
	Average Account Payable		32535.45			18782.22	
			16267.72	12.0226		9391.11	13.82
							-13.01
8	Net Capital Turnover Ratio						
	Net Sales						
	Net Working Capital						
	Net Sales	286945.06			222371.82		
	Net Working Capital						
	Current Assets		133088.25			97772.95	
	Less: Current Liabilities		89322.00			47072.27	
			43766.25	6.55631		50700.68	4.386
							49.48
9	Net Profit Ratio						
	Net Profit						
	Sales						
	Net Profit (After Taxes)	35581.65			17901.86		
			286945.06	0.124		222371.82	0.081
							54.03



10	Return on Capital Employed				
	Earning before Interest and Taxes				
	Capital Employed				
	Earning before Interest and Taxes				
	Net Profit	48081.65		24401.86	
	Add: Interest	6481.84		6531.00	
	Total	54563.49		30932.87	
	Capital Employed				
	(Total Assets - Current Liabilities)				
	Total Assets	274053.39		208611.06	
11	Less: Current Liabilities	-89322.00		-47072.27	
		363375.39	0.15016	255683.33	0.121
					24.12
11	Return on Investment				
	Profit				
	Investment	8688.31	-	29717.03	-

Reason for Variance

- 1 There is no significant change in the key financial ratio (Less than 25%)
- 2 There is no significant change in the key financial ratio (Less than 25%)
- 3 There is increased in Earning for Debts Services, Therefore ratio decreased.
- 4 There is decreased in Profit in current year , Therefore ratio decreased.
- 5 Sales is decreased and Average Stock is increased , therefore ratio is decreased.
- 6 There is increased in Earning for Debts Services, Therefore ratio decreased.
- 7 Purchase is decreased and Average Account Payable is decreased, therefore ratio is decreased.
- 8 There is no significant change in the key financial ratio (Less than 25%)
- 9 Net Profit is decreased and sales is also decreased , therefore ratio is decreased.
- 10 Net Profit is decreased, therefore ratio is decreased.
- 11 There is no earning from Investment



Consolidated Notes on Financial Statement for the year ended 31st March, 2025

In Rs.,000

	2025	2024
--	------	------

The previous year figures have been regrouped / reclassified, wherever necessary to confirm to the current year presentation

2. SHARE CAPITAL**Authorized Share Capital :**

2000000 Equity shares of Rs.10/- each

20000.00

20000.00

(Previous Year 2000000 Equity Shares)

Issued,Subscribed and Paid up :

1171944 Equity Shares of Rs.10/- each fully paid up

11719.44

11719.44

(Previous Year 1171944 Equity Shares of Rs.10/- each)

Total	11719.44	11719.44
--------------	-----------------	-----------------

The details of Shareholders holding more than 5% Shares:

Name of the Sharholders	2025		2024	
	No. of Share	% held	No. of Share	% held
Sanjay Manocha	292986	25.00	609055	51.97
Archna Manocha	135167	11.53	522264	44.56
Siddharth Manocha	40625	3.47	40625	3.47
Kartik Palta	169931	14.50	-	-
Yogesh Sachdeva	234389	20.00	-	-
Sukesh Arora	140633	12.00	-	-
Mona Sachdeva	93756	8.00	-	-
Charu Palta	64457	5.50	-	-

The details of Shareholding of Promoters:

Name of the Sharholders	2025		2024	
	No. of Share	% held	No. of Share	% held
Sanjay Manocha	292986	25.00	609055	51.97
Archna Manocha	135167	11.53	522264	44.56
Siddharth Manocha	40625	3.47	40625	3.47
Kartik Palta	169931	14.50	-	-
Yogesh Sachdeva	234389	20.00	-	-
Sukesh Arora	140633	12.00	-	-
Mona Sachdeva	93756	8.00	-	-
Charu Palta	64457	5.50	-	-

The Reconciliation of the numbers of shares outstanding is set out below:

	2025	2024
Equity Shares at the beginning of the year	1171944	1171944
Add: Share Issued during the year	-	-
Equity Shares at the end of the year	1171944	1171944

Terms/rights attached to Equity Shares

The company has only one class of equity shares having a par value of Rs.10 per share. All these shares have same rights and preferences with respect to payment of dividend, repayment of capital and voting.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.



3. RESERVES AND SURPLUS**2025****2024****Share Premium Account**

As per Last Balance Sheet

8250.48

8250.48

Add: During the year

-

-

Total(A)**8250.48****8250.48****Profit & Loss Account**

As per Last Balance Sheet

71489.60

54627.69

Add: Profit for the year

39604.07

17022.04

Less: Previous Year Adjustment

60.87

160.14

Total(B)**111032.80****71489.60****Grand Total (A+B)****119283.28****79740.08**

Consolidated Notes on Financial Statement for the year ended 31st March, 2025

In Rs.,000

	2025	2024
4.LONG TERM BORROWINGS		
Term Loan -Working Capital (SIDBI)	48740.98	53821.00
Business Term Loan	-	6681.37
Term Loan against Vehicle	-	2887.40
Total	48740.98	63389.77

Security

- (i) SIDBI Working Capital Loan secured by mortgage of Factory Building & Plant & Machinery
(ii) Term Loan against Vehicle is secured by hypothecation of Vehicle.

5.LONG TERM PROVISIONS

Deferred Tax Liability	3161.40	6689.51
Provision for Gratuity	1667.55	-
Provision for Leave Encashment	158.75	-
Total	4987.70	6689.51

6.SHORT TERM BORROWINGS

Term Loan -Working Capital (SIDBI)	22734.00	18235.00
Business Term Loan	-	300.00
Term Loan against Vehicle	-	990.93
Loan from Related Parties	15196.88	-
Total	37930.88	19525.93

Security

- (i) SIDBI Working Capital Loan secured by mortgage of Factory Building & Plant & Machinery
(ii) Term Loan against Vehicle is secured by hypothecation of Vehicle.

7. TRADE PAYABLES

(i)Micro, Small and Medium Enterprises		
-Less Than 1 Year	16803.45	8790.72
-1-2 Years	157.84	-
-2-3 Years	-	-
- More than 3 Years	-	-
(ii)Others	-	-
-Less Than 1 Year	6289.91	493.53
(iii) Disputed Dues-MSME	-	-
(iii) Disputed Dues-Others	-	-
Total	23251.20	9284.25

8.OTHER CURRENT LIABILITIES

Statutory Dues Payable	5606.60	2998.52
Salary Payable	3430.03	1802.07
Expenses Payable	2936.02	1417.48
Other Current Liabilities	5207.45	4628.14
Advance From Customer	-	1276.98
Security Depsoits	-	118.66
Total	17180.11	12241.85

9.SHORT TERM PROVISIONS

Income Tax Provisions	10914.77	6020.24
Provision for Gratuity	34.72	-
Provision for Leave Encashment	10.32	-
Total	10959.81	6020.24



Consolidated Notes on Financial Statement for the year ended 31st March, 2025

In Rs.,000

	2025	2024
11. NON CURRENT INVESTMENTS		
Investment in Equity Shares	8194.00	29717.03
Cost of Acquisition (Net of Capital Reserve)	494.31	-
Share of Profit		
Total	8688.31	29717.03
12. OTHER NON CURRENT ASSETS		
Security Deposit	3380.65	1568.42
Total	3380.65	1568.42
13. INVENTORIES		
Stock-in-Trade	71197.39	41365.60
Total	71197.39	41365.60
14. TRADE RECEIVABLE		
(Unsecured and Considered Good)		
(i) Undisputed Trade Receivable-Considered Good		
- Less Than 6 Months	50983.74	45020.54
- 6 Months-1 Year	116.02	857.11
- 1 -2 Years	245.52	740.18
- 2 -3 Years	-	525.79
- More than 3 Years	1046.78	-
(ii) Undisputed Trade Receivable-Considered Doubtful	-	-
(iii) Disputed Trade Receivable-Considered Good	-	-
(v) Disputed Trade Receivable-Considered Doubtful	-	-
Total	52392.06	47143.62
15. CASH AND CASH EQUIVALENTS		
Balance with Banks	2031.67	1391.30
Cash in Hand	385.86	152.88
FDR with Banks	3450.42	3232.08
Total	5867.94	4776.26
16. Short Term Loans & Advances		
[Unsecured-Considered Good (Unless Otherwise Stated)]		
Advance Agt Purchase	382.58	3294.90
Other Advance	1771.12	142.88
Prepaid Expense	97.78	417.40
Total	2251.48	3855.17
17. OTHER CURRENT ASSETS		
[Unsecured-Considered Good (Unless Otherwise Stated)]		
VAT Refundable	105.10	105.10
GST Input Credit	256.39	212.62
I T Refund	134.42	181.03
GST Not Reflected	883.47	133.55
Total	1379.38	632.29



Consolidated Notes on Financial Statement for the year ended 31st March, 2025

In Rs.,000

	2025	2024
18. REVENUE FROM OPERATIONS		
Sale of Products	294160.63	241238.46
Less: Inter Unit Transfer	7215.58	18866.64
Total	286945.06	222371.82
19. OTHER INCOME		
Interest on FDR	229.35	429.86
Reimbursement-Govt Schemes	375.00	1381.81
Loss on sale of Investment	-1411.99	-152.50
Total	-807.64	1659.17
20.COST OF MATERIAL CONSUMED		
Opening Stock	35909.74	34128.25
Add: Purchase during the year	154737.92	69280.36
	190647.67	103408.61
Less: Closing Stock	55850.36	35909.74
Total	134797.31	67498.87
21. PURCHASE OF STOCK IN TRADE		
Purchases of stock in trade	48057.78	79373.28
Less: Inter Unit Transfer	7215.58	18866.64
Total	40842.20	60506.64
22. CHANGES IN INVENTORIES OF FINISHED GOODS		
Inventories at the end of the Year	15347.03	5455.86
Inventories at the beginning of the Year	5455.86	6825.39
Total	-9891.17	1369.54
23.EMPLOYEE COST BENEFIT		
Wages, Salary & Incentives	32725.33	30765.89
Contribution to Provident and ESI Fund	1654.04	1197.86
Provision for Gratuity	1702.26	-
Provision for Leave Encashment	169.08	-
Staff Welfare	292.64	121.52
Total	36543.34	32085.26
24.FINANCE COST		
Bank Charges	88.94	95.63
Bank Interest	6392.90	6435.38
Total	6481.84	6531.00
25.DEPRECIATION AND AMORTISATION EXPENSES		
Depreciation and Amortisation	7007.06	6758.14
Total	7007.06	6758.14



26.OTHER OPERATING EXPENSES

Custom Duty	62.44	28.86
Clearing & Forwarding Charges	58.34	-
Power & Fuel	2554.90	1806.33
Repair & Maintance Expenses	1581.31	2375.13
Rent	2081.73	1869.29
Fright & Courier Charges	2681.58	2799.54
Conveyance & Travelling Expenses	3346.32	5727.47
Communication Expense	122.63	104.77
Office Expenses	498.48	585.01
Printing & Stationery Expenses	406.37	504.34
GST Expenses	516.30	178.07
Insurance Expenses	443.36	436.01
Fee & Taxes	264.58	402.94
Professional Fee	2569.25	2266.50
Testing fee	372.03	-
Packing Expenses	-	11.80
Audit Fee	-	125.00
Business Promotion	1484.81	2425.23
Discount Allowed	2115.37	1700.13
Commission	6.75	235.65
Water Charges	20.93	38.39
Security Charges	517.94	432.05
Festival Expenses	144.00	340.06
Tender Fee	-	245.46
Website Expenses	425.77	241.66
Total	22275.19	24879.68



Sceptre Medical (INDIA) Private Limited

Lower Ground Floor, N-1, Satyawati Colony, Ashok Vihar, Phase-111, Delhi, Ashok Vihar,
North West Delhi, Delhi, India, 110052

CIN: U33112DL2010PTC204626

Email: accounts@sceptremedical.com Telephone: 9811053705


NOTICE

Notice is hereby given that the 15th (Fifteenth) Annual General Meeting of the Members of Sceptre Medical (INDIA) Private Limited will be held on Tuesday, the 30th day of September 2025 at 10:30 A.M. at the registered office of the Company situated at Lower Ground Floor, N-1, Satyawati Colony, Ashok Vihar, Phase-111, Delhi, Ashok Vihar, North West Delhi, Delhi, India, 110052 to transact the following business:

ORDINARY BUSINESS:

To consider and adopt the Audited Financial Statements (including the Consolidated Financial Statements) of the Company for the financial year ended March 31, 2025 and the reports of the Board of Directors ("the Board") and Auditors thereon

By Order of the Board
For Sceptre Medical (INDIA) Private Limited


YOGESH SACHDEVA
(Director)
DIN: 00077095


KARTIK PALTA
(Director)
DIN: 01543913

Place: Delhi
Date: 02.09.2025

NOTES:

1. A member entitled to attend and vote is entitled to appoint a proxy or proxies to attend and, on a poll, to vote on his behalf and the proxy need not be a member. A person can act as a proxy on behalf of members not exceeding 50 and holding in the aggregate not more than 10% of the total Share Capital of the Company carrying voting rights. In case a proxy is proposed to be appointed by a member holding more

than 10% of the total Share Capital of the Company carrying voting Rights, than such proxy shall not act as a proxy for any other person member.

2. The Notice is being sent to all the Members along with the copy of the Annual Report including the Financial Statements, Boards Report etc.
3. All documents referred to in the accompanying Notice are open for inspection at the Registered Office of the Company on all working days, except Sundays between 10.00 A.M. and 2.00 P.M up to the date of the Annual General Meeting.
4. Corporate Members intending to send their authorized representatives are requested to send a duly certified copy of the Board Resolution authorizing their representatives to attend and vote at the Annual General Meeting.

Sceptre Medical (INDIA) Private Limited

Lower Ground Floor, N-1, Satyawati Colony, Ashok Vihar, Phase-111, Delhi,
Ashok Vihar, North West Delhi, Delhi, India, 110052

CIN: U33112DL2010PTC204626

Email: accounts@sceptremedical.com Telephone: 9811053705

DIRECTORS REPORT FOR THE FINANCIAL YEAR 2024-2025

To,
The Members,
Sceptre Medical (INDIA) Private Limited

The Board of Directors are pleased to present the 15th (Fifteenth) Annual Report and the Company's Audited Financial Statements for the financial year ended March 31, 2025.

1 FINANCIAL RESULTS

The Company's financial performance for the year ended March 31, 2025 is summarized below:

	Amount in Rs.	
	Year Ended 31.03.2025	Year Ended 31.03.2024
Net Sales/ Receipts	28,61,37,412	22,40,30,991
Total Expenditure	23,80,55,762	19,96,29,127
Profit before taxes	4,80,81,650	2,44,01,864
Less: Provision for Tax		
Current Tax	1,25,00,000	65,00,000
Deferred Tax	(35,28,110)	8,79,822
Profit after taxes	3,91,09,760	1,70,22,042
Earnings per share	33	15

2 FINANCIAL HIGHLIGHTS

The Company's financial performance for the year ended March 31, 2025 is summarized below:

The Profit after Tax is Rs. 39109760 as compared to Rs. 17022042 in the previous year.

3	DIVIDEND The Board of Directors of your Company have not recommended any dividend for the Financial Year ended 31st March 2025.
4	CHANGE IN THE NATURE OF BUSINESS AND MATERIAL CHANGES BETWEEN THE DATE OF THE BOARD REPORT AND END OF FINANCIAL YEAR There has been no change in the nature of business of the Company. There have been no material changes and commitments affecting the financial position of the Company between the end of the financial year and the date of this report. One Change that take place is: Registered Office Address changed within the local limits of city, town or village FROM 14, Central Market, First Floor, Ashok Vihar, Phase-I , North West- New Delhi -110052 TO Lower Ground Floor, N-1, Satyawati Colony, Ashok Vihar, Phase-111, Delhi, Ashok Vihar, North West Delhi, Delhi, Delhi, India, 110052 On 04.02.2025 vide SRN AB2854444
5	SUBSIDIARY & ASSOCIATE COMPANY During the financial year 2024–25, the Company acquired 40% of the equity share capital of M/s SCEPTRE MEDICAL DEVICES PRIVATE LIMITED (CIN: U33100DL2002PTC113888)., as a result of which the said company became an Associate Company of the Company within the meaning of Section 2(6) of the Companies Act, 2013. This company earned a net profit of Rs.12,89,509 for the year ended 31st March 2025 (Previous Year Net Profit of Rs. 20,80,465) The statement containing salient features of financial statements of subsidiaries, associates and joint ventures, pursuant to the provisions of Section 129(3) of the Companies Act, 2013 are being annexed herewith in Annexure-I A summary of the consolidated financial performance of the company for the Financial Year ending March 2025 and March 2024 consolidating the results of the associate company M/s SCEPTRE MEDICAL DEVICES PRIVATE LIMITED is given below.

PARTICULARS	Amount in Rs.	
	YEAR ENDED 31.03.2025	YEAR ENDED 31.03.2024
Total Income	28,61,37,412	22,40,30,991
Total Expenses	23,80,55,762	19,96,29,127
Profit before Tax	4,80,81,650	2,44,01,864
Less: Provision for Tax		
Current Tax	1,25,00,000	65,00,000
Deferred Tax	-35,28,110	8,79,822
Profit after Tax	3,91,09,760	1,70,22,042
Share of Associates	4,94,312	----
Consolidated Profit	39,60,4072	1,70,22,042
Earning per equity share		
Basic & Diluted	34	15

6	DIRECTORS RESPONSIBILITY STATEMENT Pursuant to Section 134(5) of the Companies Act, 2013, the Board of Directors, to the best of their knowledge and belief and according to the information and explanations obtained by them, your Directors confirm that:
i)	in the preparation of the annual accounts of the year ended March 31, 2025, the applicable accounting standards have been followed along with proper explanations relating to any material departures, if any;
ii)	they have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company as at March 31, 2025 and of the profit of the Company for the year ended on that date;
iii)	they have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
iv)	that the Annual Accounts are prepared on a going concern basis;
v)	that they have laid down proper internal financial controls to be followed by the company and that internal financial controls are adequate and are operating effectively; and

vi)	they have devised proper systems to ensure compliance with the provisions of all applicable laws and these systems are adequate and operating effectively.
7.	RELATED PARTY TRANSACTIONS Related party transactions were entered into by the Company during the financial year. Related party transactions entered by the Company during the financial year were in the ordinary course of business and on arm's length basis which did not conflict with the interest of the Company. Details of the same are enclosed in Annexure-II
8.	CORPORATE SOCIAL RESPONSIBILITY POLICY AND RELATED DISCLOSURES/COMPLIANCES The Company does not cross the threshold limit provided under Section 135 of the Companies Act, 2013 read with the Companies (Corporate Social Responsibility Policy) Rules, 2014 relating to Corporate Social Responsibility, hence CSR is not applicable to the Company.
9	RISK MANAGEMENT The Board has adopted the procedures for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting record, and the timely preparation of reliable financial disclosures.
10	INTERNAL FINANCIAL CONTROLS SYSTEM AND THEIR ADEQUACY The Company has in place adequate systems of internal controls to ensure compliance with policies and procedures, including monitoring procedures to ensure that all assets and investments are safeguarded against loss from unauthorized use or disposition.
11	DIRECTORS AND KEY MANAGERIAL PERSONS There has been change in the constitution of Board during the period under review. During the year Sh. Kartik Palta having DIN: 01543913 Sh. Sukesh Arora having DIN: 10682240 and Sh. Yogesh Sachdeva having DIN: 00077095 were appointed as Additional Directors of Company on 01.01.2025. These Additional Directors were regularized on Board on 03.03.2025.


	Sh. Sukesh Arora having DIN: 10682240 has resigned from Directorship on 25.06.2025. Particulars of remuneration in terms of Section 197(12) of the Act and Rule 5(2) and (3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are applicable to listed public companies. Your Company being a private limited company hence the same has not been provided in the report.
12	SECRETARIAL AUDIT Provisions of Section 204 of the Companies Act, 2013 relating to Secretarial Audit is not applicable to your company.
13	AUDITOR AND EXPLANATION ON AUDITOR QUALIFICATION: Pursuant to the provisions of the section 139 of the Act and the rules framed there under, M/s. RGMG & CO., Chartered Accountants (FRN: 006329N) were appointed as Statutory Auditors of the Company to hold office till the conclusion of AGM of the Company to be held in the year 2029. Auditor's Report for the current financial year is annexed herewith for your kind perusal and information. The report of the Statutory Auditors along with notes to Schedules is enclosed to this Report. The statutory Auditors report submitted by them does not contain any qualifications, reservations, adverse remarks or disclaimers on the financial statements of the Company for the financial year 2024-2025.
14	NUMBER OF MEETINGS OF THE BOARD 8 Meetings of the Board of Directors were held during the year. The meetings were held on 15.04.2024, 31.07.2024, 05.09.2024, 19.12.2024, 01.01.2025, 04.02.2025, 08.03.2025 and 31.03.2025 All the directors of the company attended all the meetings.
15	DEPOSITS The company has not accepted any deposits u/s 73 of Companies Act, 2013 during the year under review.
16	TRANSFER TO RESERVE The Board of Directors does not propose to transfer any profits to any reserve.

17	SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS During the year under review, there were no significant or material orders which were passed by the regulators or courts or tribunals which may impact the going concern status and company's operation in future.
18	DECLARATION BY INDEPENDENT DIRECTOR Provisions of Section 149 relating to Independent Directors is not applicable to your Company, therefore, no statement on declaration to be given by independent directors is being enclosed herewith.
19	CHANGES IN SHARE CAPITAL The paid-up Equity Share Capital as on 31st March 2025 was Rs. 1,17,19,440/. There was no change in the share capital of the Company during the year under review.
20	INTER CORPORATE LOANS AND INVESTMENTS There was no loans and guarantee made by the Company under section 186 of the Companies Act, 2013 during the year, under review and hence the said provisions are not applicable. As far as Inter corporate investment is concerned, Company made investments in Properties. Company made an investment by buying 40% shares in Sceptre Medical Devices Private Limited (CIN: U33100DL2002PTC113888)
21	TRANSFER OF UNCLAIMED/UNPAID AMOUNT TO INVESTOR EDUCATION AND PROTECTION FUND During the Financial Year 2024-2025, no amount was required to be transferred to the Investor Education and Protection Fund.
22	PARTICULARS REGARDING CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND EXPENDITURE Since the company carries out manufacturing activity, the particulars relating to conservation of energy, technology absorption and other particulars required pursuant to Section 134(3) (m) read with Rule 8 (3) of the Companies (Accounts) Rules, 2014 are applicable to Company. Details of the same are enclosed in Annexure-III There were no foreign exchange earnings. There were foreign exchange expenditures. Therefore the directors have nothing to report on the foreign exchange earnings. Foreign exchange expenditures pursuant to Section 134(3) (m) of the Companies Act, 2013 are disclosed. Details of the same are enclosed in Annexure-III

23	WEB LINK OF ANNUAL RETURN Pursuant to Section 92(3), Company https://www.sceptremedical.in has a Website, a copy of Annual Return will be placed on the website of the Company.
24	INSTANCES OF FRAUD REPORTED BY THE AUDITORS There have been no instances of fraud reported by the Auditors under Section 143(12) of the Act.
25	MATERNITY COMPLIANCE DISCLOSURE: The Company confirms that it has women employees on its rolls during the financial year ended 31st March, 2025. However, no case of maternity benefit arose during the year, and accordingly, no maternity leave, medical benefits, or nursing breaks were availed or provided under the provisions of the Maternity Benefit Act, 1961 during the year under review.
26	Statutory disclosures The directors' responsibility statement as required by section 134(5) of the Companies Act, 2013, reports above. The provisions of section 148 of the Companies Act, 2013, are not applicable to the Company. Accordingly, there is no requirement of maintenance of cost records as specified under sub-section (1) of section 148 of the Companies Act, 2013. Pursuant to the legislation 'The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013', the Company has a policy on Prevention of Sexual Harassment at Workplace. During the year under review, no complaint was received from any of the employees, Neither any application was made nor any proceeding pending under the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the financial year. Loans were taken from banks or Financial Institutions but there are no disclosure relating to details of difference between the amount of valuation done at the time of one-time settlement and valuation done while taking loan from the Banks or Financial Institutions. Loans received from the Directors were out of their own funds and not from any borrowed funds.

27	COMPLIANCES OF ALL LAWS The Board hereby states that the company has devised proper systems to ensure compliance of all laws applicable to the company.
28	SECRETARIAL STANDARDS The Directors state that the Company has complied with both the applicable Secretarial Standards i.e. SS- 1 and SS-2 relating to 'Meetings of the Board of Directors' and 'General Meetings', respectively.
29	DISCLOSURE UNDER SEXUAL HARASSMENT OF WOMEN AT THE WORKPLACE (PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013 The Company has in place 'Prevention of Sexual Harassment Policy' in line with the requirements of The Sexual Harassment of Women at the Workplace (Prevention, Prohibition & Redressal) Act, 2013. An Internal Complaints Committee (ICC) is in place to redress complaints received regarding sexual harassment. The following is a summary of sexual harassment complaints received and disposed off during the year, Number of complaints received: Nil, Number of complaints disposed off: NA.
30	APPRECIATION Your Directors wish to place on record their sincere appreciation to the shareholders, employees and bankers for their co-operation and support.

By Order of the Board
For Sceptre Medical (INDIA) Private Limited


YOGESH SACHDEVA
(Director)
DIN: 00077095


KARTIK PALTA
(Director)
DIN: 01543913

Place: Delhi
Date: 02.09.2025

Sceptre Medical (INDIA) Private Limited

Lower Ground Floor, N-1, Satyawati Colony, Ashok Vihar, Phase-111, Delhi, Ashok Vihar, North West Delhi, Delhi, India, 110052

CIN: U33112DL2010PTC204626

Email: accounts@sceptremedical.com Telephone: 9811053705

ANNEXURE-I

FORM AOC-1

(Pursuant to Section 129 (3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures)

Statement containing salient features of financial statements of subsidiaries/ associates companies/ joint ventures

Part "B": Associates and Joint Ventures

PARTICULARS	DETAILS
1. Name of associates/Joint Ventures	SCEPTRE MEDICAL DEVICES PRIVATE LIMITED
2. Latest audited Balance Sheet Date	31/03/2025
3. Date on which Associate/Joint Venture was associated or acquired	16/04/2024
4. Shares of Associate/Joint Ventures held by the company on the year end	
No.	372000
Amount of Investment in Associates/Joint Venture	3720000
Extend of Holding%	40%

5. Description of how there is significant influence	Control of more than 20% of total share capital
6. Reason why the associate/joint venture is not consolidated	NOT APPLICABLE
7. Net worth attributable to shareholding as per latest audited Balance Sheet	6688000
8. Profit/Loss for the year	
i. Considered in Consolidation	494000
ii. Not Considered in Consolidation	

1. Names of associates or joint ventures which are yet to commence operations. NIL

2. Names of associates or joint ventures which have been liquidated or sold during the year.
NIL

For and on the behalf of Board of Directors

Sceptre Medical (INDIA) Private Limited


YOGESH SACHDEVA

(Director)

DIN: 00077095


KARTIK PALTA

(Director)

DIN: 01543913

Place: Delhi

Date: 02.09.2025

Sceptre Medical (INDIA) Private Limited

Lower Ground Floor, N-1, Satyawati Colony, Ashok Vihar, Phase-111, Delhi, Ashok Vihar,
North West Delhi, Delhi, India, 110052

CIN: U33112DL2010PTC204626

Email: accounts@sceptremedical.com Telephone: 9811053705

ANNEXURE-II

FORM NO. AOC-2

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

01.Details of material contracts or arrangement or transactions at arm's length basis

S.No	Particulars	Details
1	Name(s) of the related party and nature of relationship	Sceptre Medical Devices Private Limited and related through Director
2	Nature of contracts/ arrangements/ transactions	Purchase and Sale of Goods
3	Duration of the contracts/ arrangements/ transactions	One Year
4	Salient terms of the contracts or arrangements or transactions including the value, if any	Value of Transactions: Purchase = Rs 53,390/- Sale = Rs 49,650/-
5	Date of approval by the Board, if any	15.04.2024
6	Amount paid as advances, if any	-----

02.Details of material contracts or arrangement or transactions at arm's length basis

S.No	Particulars	Details
1	Name(s) of the related party and nature of relationship	M.S. Medicals Private Limited and related through Director
2	Nature of contracts/ arrangements/ transactions	Sale of Goods
3	Duration of the contracts/ arrangements/ transactions	One Year
4	Salient terms of the contracts or arrangements or transactions including the value, if any	Value of Transaction = Sale : Rs 8,61,22,629 Purchase: NIL
5	Date of approval by the Board, if any	15.04.2024
6	Amount paid as advances, if any	----

03.Details of material contracts or arrangement or transactions at arm's length basis

S.No	Particulars	Details
1	Name(s) of the related party and nature of relationship	Mr. Sanjay Manocha Director
2	Nature of contracts/ arrangements/ transactions	Remuneration
3	Duration of the contracts/ arrangements/ transactions	One Year
4	Salient terms of the contracts or arrangements or transactions including the value, if any	Value of Transactions: Rs 39,00,000
5	Date of approval by the Board, if any	15.04.2024
6	Amount paid as advances, if any	----

04.Details of material contracts or arrangement or transactions at arm's length basis

S.No	Particulars	Details
1	Name(s) of the related party and nature of relationship	Mr. Siddhartha Manocha Director's Son

2	Nature of contracts/ arrangements/ transactions	Remuneration
3	Duration of the contracts/ arrangements/ transactions	One Year
4	Salient terms of the contracts or arrangements or transactions including the value, if any	Value of Transactions: Rs 9,75,000
5	Date of approval by the Board, if any	15.04.2024
6	Amount paid as advances, if any	----

05.Details of material contracts or arrangement or transactions at arm's length basis

S.No	Particulars	Details
1	Name(s) of the related party and nature of relationship	Ms. Archana Manocha Director
2	Nature of contracts/ arrangements/ transactions	Remuneration
3	Duration of the contracts/ arrangements/ transactions	One Year
4	Salient terms of the contracts or arrangements or transactions including the value, if any	Value of Transactions: Rs 27,00,000
5	Date of approval by the Board, if any	15.04.2024
6	Amount paid as advances, if any	----

06.Details of material contracts or arrangement or transactions at arm's length basis

S.No	Particulars	Details
1	Name(s) of the related party and nature of relationship	Mr. Kartik Palta-Director
2	Nature of contracts/ arrangements/ transactions	Remuneration


3	Duration of the contracts/ arrangements/ transactions	One Year
4	Salient terms of the contracts or arrangements or transactions including the value, if any	Value of Transactions: Rs 9,30,000
5	Date of approval by the Board, if any	15.04.2024
6	Amount paid as advances, if any	----

07.Details of material contracts or arrangement or transactions at arm's length basis

S.No	Particulars	Details
1	Name(s) of the related party and nature of relationship	Mr. Yogesh Sachdeva Director
2	Nature of contracts/ arrangements/ transactions	Remuneration
3	Duration of the contracts/ arrangements/ transactions	One Year
4	Salient terms of the contracts or arrangements or transactions including the value, if any	Value of Transactions: Rs 7,50,000
5	Date of approval by the Board, if any	15.04.2024
6	Amount paid as advances, if any	----


For and on the behalf of Board of Directors

Sceptre Medical (INDIA) Private Limited


YOGESH SACHDEVA

(Director)

DIN: 00077095


KARTIK PALTA

(Director)

DIN: 01543913

Place: New Delhi

Date: 02.09.2025

Sceptre Medical (INDIA) Private Limited

Lower Ground Floor, N-1, Satyawati Colony, Ashok Vihar, Phase-111, Delhi, Ashok Vihar, North West Delhi, Delhi, India, 110052

CIN: U33112DL2010PTC204626

Email: accounts@sceptremedical.com Telephone: 9811053705

ANNEXURE-III

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE OUTGO

(A) Conservation of Energy :

1. Steps taken for conservation of energy and impact:

The Company has taken various measures for conservation of energy, details of which are as under:

- **HVAC System Optimization:** Optimization of Air Handling Units (AHUs) and cleanroom utilities to improve energy efficiency and reduce power consumption.
- **Process Equipment Efficiency:** Use of energy-efficient machinery and preventive maintenance practices to minimize energy loss during pharmaceutical manufacturing.
- **Lighting Efficiency:** Replacement of conventional lighting with LED lighting across production areas, laboratories, and warehouses.
- **Compressed Air Management:** Regular monitoring and maintenance of compressed air systems to reduce leakages and avoid energy wastage.

Impact:

These initiatives have helped in optimizing power consumption and resulted in overall reduction in energy costs and improved operational efficiency.

2. Steps taken by the Company for utilizing alternate sources of energy:

At present, the Company has not installed or utilized any alternate source of energy, including solar power or other renewable energy sources. However, the Company continues to evaluate

feasible options for adopting alternate and renewable energy sources as part of its long-term sustainability and cost-optimization strategy.

3. Capital investment on energy conservation equipment:

The Company has made capital investments in energy-efficient equipment and utility optimization, including:

- Installation of energy-efficient motors and utility equipment.
- Improvement in monitoring and control systems for utilities to reduce energy consumption.

These investments support efficient energy utilization across manufacturing operations.

B) Technology Absorption, Adaptation and Innovation:

1. Efforts made towards technology absorption:

The Company continues to focus on absorption and adaptation of modern technologies to enhance efficiency, quality, and regulatory compliance in pharmaceutical manufacturing. Key initiatives include:

- **Process Optimization:** Adoption of improved manufacturing processes and validated production techniques to enhance product consistency, yield, and efficiency.
- **Automation & Digital Controls:** Increased use of PLC-based controls and automated systems in critical manufacturing and utility operations to reduce manual intervention and improve process reliability.
- **Quality & Compliance Systems:** Strengthening of Quality Management Systems (QMS) in line with GMP requirements, including upgraded laboratory instruments and improved documentation and traceability systems.
- **Regulatory Alignment:** Continuous upgradation of systems and procedures to comply with evolving regulatory requirements under Indian and international pharmaceutical standards.

2. Benefits derived from technology absorption:

The above initiatives have resulted in the following benefits:

- Improved manufacturing efficiency and reduced process variability.
- Enhanced product quality, safety, and regulatory compliance.
- Reduction in production downtime and operational costs.

- Better utilization of resources and improved overall productivity.

3. Information regarding technology imported during the last three years:

The Company has not imported any specific technology during the last three financial years. The technological improvements have been achieved primarily through in-house process development, optimization of existing machinery, and adoption of best industry practices.


(C) FOREIGN EXCHANGE EARNINGS AND OUTGO:

There were no foreign exchange earnings.

There was foreign exchange expenditure of Travel amounting to Rs 421575/-

For and on the behalf of Board of Directors

Sceptre Medical (INDIA) Private Limited



YOGESH SACHDEVA

(Director)

DIN: 00077095



KARTIK PALTA

(Director)

DIN: 01543913

Place: New Delhi

Date: 02.09.2025